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a b s t r a c t
The diagnostic utility of obtaining chest and abdomen computed tomography (CT) to evaluate for invasive
fungal infection (IFI) before and after hematopoietic stem cell transplant (HSCT) remains unclear. The study
was conducted as a quality improvement project. Chest and abdomen CT of patients who underwent an
allogeneic HSCT over a 13-month period were reviewed. Scans included those performed pretransplant in all
patients and days 0 to 100 post-transplant in selected patients. Sixty-six patients had chest and abdomen CT
scans pretransplant. Chest CT was suggestive of IFI in 9 patients (13.6%), including 3 patients with prior
history of IFI. After transplant, 37 patients had an initial chest CT and 14 patients an initial abdominal CT. The
ﬁrst chest CT post-transplant was suggestive of IFI in 3 patients; all had an abnormal CT pretransplant. After
the initial post-transplant evaluation, 15 patients had 28 additional CT scans of the chest and 12 patients 19
additional CT scans of the abdomen. An abnormal chest CT with proven evidence of IFI was seen in only 1
patient. None of the 99 abdominal CT scans performed pre- or post-transplant had evidence of IFI. There is
little beneﬁt in obtaining abdominal CT scans in HSCT patients for detecting IFI either pre- or post-transplant.
 2015 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Radiation risk from computed tomography (CT) imaging is
cumulative and in an unselected population increases the risk
of subsequent solid tumors, particularly in younger patients,
girls, and in those who undergo CT imaging of the abdomen
and pelvis [1]. A radiation-induced solid tumor is projected to
result from every 300 to 390 abdomen/pelvis scans for girls
[1]. The risk of leukemia in children is estimated at .8 to 1.0
cases per 10,000 abdomen/pelvis CT scans [1]. The Childhood
Cancer Survivor Study reported the 30-year cumulative inci-
dence of secondary malignant neoplasms in 14,359 5-year
survivors of childhood cancer to be 20.5% [2]. The radiation
risk of CT imaging may be higher in those who have under-
gone an allogeneic hematopoietic stem cell transplant (HSCT)
because of more frequent imaging, exposure to chemo-
therapy, and radiation therapy in some patients.
In1982, Bartleyet al. [3] reported the results of CTscanning
to diagnose hepatic and systemic invasive fungal infections
(IFIs) in children undergoing treatment for leukemia at St.
Jude Children’s Research Hospital in Memphis, Tennessee.
Subsequently, CT imaging of the abdomen was incorporated
as part of routine screening in patients with unexplained
prolonged fever with neutropenia and as part of pre-HSCT
evaluation studies. In the present era of prophylactic
antifungal therapy,wehypothesize that thediagnosticbeneﬁt
of this approach is limited, may be outweighed by the radia-
tion risk of CT imaging, and, when considered together with
the risks of sedation and contrast administration, represents
poor utilization of resources with limited beneﬁt for the
patient.
METHODS
The study was conducted as a quality improvement project and
approved by the St. Jude Children’s Research Hospital institutional review
board. Two senior pediatric radiologists at our institution (S.C.K. and R.A.K.)
reviewed the CT scans of chest and abdomen (CAF) to look for evidence of IFI
in all children who underwent allogeneic HSCT between September 1, 2012
and September 30, 2013. Scans reviewed included those performed pre-
HSCT in all patients as part of routine pretransplant evaluation and days
0 to 100 post-HSCT in those with signs and symptoms suggestive of IFI or
with unexplained prolonged fever with neutropenia, obtained at the
discretion of the requesting physician.
Standardized CAF were obtained using 3.75-mm (in children weighing
 11.5 kg) and 5-mm (in children weighing > 11.5 kg) collimated helical
images through the chest and abdomen, reconstructed in standard (soft
tissue) and lung algorithm, and reformatted in coronal and sagittal planes.
All scans were reviewed at lung, soft tissue, and bone window/levels.
Weight-based dose modulation was used for all patients weighing at least
31.5 kg; patients under 31.5 kg were imaged at 100 kVp, whereas patients 
31.5 kg were imaged at 120 kVp. The noise index for patients weighing up to
11.5 kgwas 12.35 (chest) and 9.88 (abdomen) and for patients weighing over
11.5 kg was 11.57 and 9.83, respectively. Forty percent adaptive statistical
iterative reconstruction (ASiR, General Electric Healthcare, Waukesha, WI)
was used for all studies on all patients. All CAF studies were performed
during i.v. administration of 2.0 mL/kg iodixanol 270 mg-I/mL to a
maximum of 150 mL. All studies were performed on a LightSpeed VCT XTe
64 detector scanner (General Electric Healthcare, Waukesha, WI).
Transplant-related variables were abstracted from a prospectively
collected database that included patient demographics, underlying diag-
nosis, remission status, donor and product type, conditioning regimen,
symptoms and signs suggestive of IFI if present, grades II to IV graft-versus-
host disease, and pre-HSCT absolute neutrophil count (ANC). Screening on
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whole blood for galactomannan was performed pre-HSCT and once weekly
post-HSCT on all patients. Galactomannan index value  .5 was considered
positive. Microbiologic records were reviewed to identify patients with IFI
deﬁned according to accepted criteria [4]. Changes to antifungal therapy
based on CT scan ﬁndings were noted.
Statistical Analysis
The ﬁrst evaluation date of CT scan before and after transplant was used
for analysis. CT scans whose evaluation date exceeded 100 days post-
transplant were not considered. Descriptive statistics such as frequencies/
percentages for categorical variables andmean, median, range, and standard
deviation for continuous variables were provided for pre- and post-
transplant data. Fisher’s exact test (for categorical variables) and Wilcoxon
rank sum test (for quantitative variables) were used to compare patients
with and without IFI as suggested by chest CT pre- and post-transplant.
McNemar’s exact test was used to compare patients with and without IFI
as suggested by chest CT pre- and post-transplant. Clinical variables tested
included age at transplant, gender, underlying disease, remission status,
transplant and product type, receipt of total body irradiation (TBI), presence
of symptoms and signs of IFI, ANC, and galactomannan test if positive. All
reported P values are 2-sided and are considered signiﬁcant if <.05. Statis-
tical analyses were performed with SAS software, version 9.3 (SAS Institute,
Cary, NC).
RESULTS
Sixty-six patients had CAF pretransplant. Demographics
of these patients are presented in Table 1. Seven patients had
a history of proven IFI in the lung (n¼ 4), extremity (1), sinus
(1), and blood (1) (Figure 1). All patients tested negative for
galactomannan in whole blood pretransplant. Of these 66
patients, pretransplant chest CT was abnormal in a patient
who had a focal nodule in the right lower lobe, which was
completely resected with positive culture for Aspergillus
fumigatus (1), in a patient with a nodular opacity in the left
upper lobe with history of Candida parapsilosis fungemia
(patient 2), and in a third patient with proven Aspergillus spp.
infection in a previous HSCT with resolving opacities before
the current transplant (patient 3). The remaining 4 patients
had complete resolution of their IFI pretransplant.
Six patients had no prior history of IFI but had small
unilateral or bilateral pulmonary nodules not amenable to
biopsy. Galactomannan in whole blood and testing for
endemic mycoses were negative in all patients. The 7 pa-
tients with prior history of IFI and 6 asymptomatic patients
with pulmonary nodules received empiric antifungal therapy
post-transplant. None of the 66 patients studied had evi-
dence of IFI on abdominal CT scan.
Thirty-seven patients CT imaging post-transplant. De-
mographics of these patients are presented in Table 1.
Indications for performing scans for the ﬁrst evaluation
post-transplant included prior history of IFI or evidence
thereof in pretransplant CT with or without a history of
unexplained fever with prolonged neutropenia (7 patients),
unexplained fever with prolonged neutropenia (14 pa-
tients), increased respiratory rate and hypoxia (8 patients),
abnormal pulmonary function tests (2 patients), C. albicans
fungemia (1 patient), assessment of response in patients
with solid tumor receiving an allogeneic HSCT (2 patients),
and other causes, including rising Epstein-Barr virus DNA in
blood (3 patients). An abnormal chest CT suggestive of IFI
was seen in 3 patients, all of whom had an abnormal chest
CT pretransplant: 1 patient (patient 2) had widespread
nodular opacities post-transplant, whereas 2 patients had
nodules on chest CT with no prior history suggestive of IFI
and developed fever and more nodular opacities post-
transplant. Galactomannan was negative and the nodules
were not amenable to biopsy. Antifungal therapy was
modiﬁed with addition of liposomal amphotericin for 1
patient (patient 2) and voriconazole for the other 2 patients.
Three patients had positive galactomannan post-transplant
with a normal chest CT. Two of these patients had chest
CT suggestive of IFI pretransplant. An abdominal CT was
performed with the chest CT in 14 patients. None had
ﬁndings suggestive of IFI.
None of the variables, including age (P ¼ .90), gender (P ¼
.28), transplant product (P¼ .44), TBI conditioning (P¼ 1.00),
or ANC (P ¼ .62), was signiﬁcant in predicting abnormalities
suggestive of IFI in pretransplant CT. None of the variables,
including age (P ¼ .36), gender (P ¼ 1.00), transplant product
(P ¼ .32), TBI conditioning (P ¼ 1.00), or ANC (P ¼ .26), was
signiﬁcant in predicting abnormalities suggestive of IFI in
post-transplant CT. Abnormal pre- and post-transplant chest
CT were not statistically discordant (P ¼ .25).
After the initial post-transplant evaluation, 15 patients
had 28 additional CT scans of the chest and 12 patients 19
additional CT scans of the abdomen. Indications for per-
forming these scans included fever with increased C-reactive
protein (4 patients), increased respiratory rate and hypoxia
(3 patients), C. albicans fungemia (1 patient), assessment of
response in patients with solid tumor (2 patients), abdom-
inal pain and diarrhea (2 patients), and other causes (3
patients).
An abnormal chest CT suggestive of IFI was seen in patient
4, a 1-year-old male with acute lymphoblastic leukemia who
received a cord HSCT. The patient subsequently developed
C. albicans fungemia 5 days post-HSCT that was broadly
susceptible to antifungals; chest CT was normal. He
responded poorly to a combination of micafungin and lipo-
somal amphotericin and developed nodular lesions in both
lungs on a follow-up chest CTwith no abnormalities detected
on abdominal CT (Figure 2). Biopsy of the nodules revealed
budding yeast with pseudohyphae. Therapy was changed to
micafungin with voriconazole, to which he responded. He
succumbed to a relapse of his leukemia. None of the 12 pa-
tients with abdominal CT obtained after the ﬁrst post-
transplant CT had ﬁndings suggestive of IFI.
Table 1
Demographics of Patients Who Had Evaluation of the Chest and Abdomen
for Fungus with Computed Tomography before and Within 100 Days Post-
HSCT
Characteristic CAF Pre-HSCT
(n ¼ 66)
CAF Days 0-100
Post-HSCT (n ¼ 37)
Age, yr
Mean (SD) 9.1 (6.4) 9.6 (6.1)
Median (Range) 8.8 (.2-20.4) 9.1 (.6-20.4)
Male sex 36 (55%) 18 (49%)
Diagnosis heme malignancy 58 (87%) 32 (87%)
Remission 28 (42%) 20 (54%)
Total body irradiation 19 (29%) 13 (35%)
Product type
Bone marrow 37 (56%) 18 (48%)
Peripheral blood 24 (36%) 15 (41%)
Cord 5 (8%) 4 (11%)
History IFI 7 (11%) 4 (11%)
Positive galactomannan 0 (0) 3 (8%)
ANC, cells/mL
Mean (SD) 1027 (1276) 892 (1233)
Median (range) 500 (0-4400) 500 (0-4400)
CT chest-suggestive IFI 9 (14%) 3 (8%)
CT abdomen-suggestive IFI 0 (0) 0 (0)
Transplant order
First transplant 50 (76%) 27 (73%)
Second transplant 15 (23%) 10 (27%)
Subsequent transplant 1 (1%) 0 (0)
SD indicates standard deviation.
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DISCUSSION
Our study demonstrates that none of the patients who
had an abdominal CT evaluating for IFI had any ﬁndings
suggestive of the same. Ninety-nine abdominal CT scans
were done on 66 patients over 13 months, exposing them to
radiation risk without affecting change in antifungal therapy.
Radiation-induced malignancies because of multiple
radiation-based imaging studies have no known threshold
dose and may have additive effects with chemotherapy and
TBI used as preparative regimen for transplant. Latency pe-
riods may span decades [5]. A third of our patients received
TBI, and one fourth were undergoing a second HSCT. In
addition, sedation if needed and i.v. contrast administration
for abdominal CT is not without risk.
The practice of obtaining a routine abdominal CT scan
pretransplant was started at our institution after recognition
of the entity of hepatosplenic fungal abscesses by imaging
children with leukemia undergoing therapy [3]. Mortality
from this disease is substantial in the absence of early
recognition and prompt therapy. Over an 11-year period
between 1980 and 1990, 35 children at our institution had CT
ﬁndings compatible with IFI in the liver, spleen, and/or kid-
neys conﬁrmed by culture, biopsy, or autopsy [6]. With early
diagnosis of this condition, the 3-month survival rate was
86% [6].
Abdominal fungal disease occurs in patients with known
fungemia [3]. Improved culture methodologies that increase
the sensitivity of diagnostic fungal culture, allow rapid initi-
ation of therapy, and allow a decline in incidence of IFI with
prophylactic antifungals may explain the low yield of routine
abdominal CT imaging for IFI. In a review of 355 autopsies
performed between 1990 and 1994 on HSCT patients, ﬂu-
conazole prophylaxis resulted in a decrease of Candida spp.
infections from 27% to 8%, whereas Aspergillus spp. infections
increased from 18% to 29% [7]. With the advent of vor-
iconazole prophylaxis in the 2000s, the incidence of invasive
aspergillosis at our institution has dramatically declined [8].
In a prior retrospective study of allogeneic HSCT patients at
our institution, routine imaging of the abdomen in asymp-
tomatic patients pretransplant did not reveal any previously
unknown abnormalities requiring changes in antifungal
therapy [9]. Our current study validates this ﬁnding.
Our patients were followed up to 100 days post-
transplant to study the evolution of imaging ﬁndings in
those with evidence of IFI pretransplant and utility of
obtaining chest and abdominal CT scans in patients with
unexplained fever with neutropenia. Typhlitis and hep-
atosplenic fungal infection are often listed as the reasons for
performing an abdominal CT examination in this setting.
However, typhlitis on imaging generally is preceded by
symptoms and in the absence of which is extremely unlikely.
Abdominal ultrasound has been shown to be a sensitive
modality for diagnosis of typhlitis at our institution [10] and
by others [11]. Ultrasound is suggested as a sensitive, cost-
effective, and safe modality for detection of hepatosplenic
candidiasis [12]. Abdominal ultrasound is the recommended
modality for diagnostic imaging in patients with prolonged
fever and neutropenia by some oncology groups [13].
In a review of cases of aspergillosis over a 34-year period
at our institution, no cases of isolated abdominal or pelvic
disease were noted; the lung was the most common organ
involved with concurrent abdominal disease [14]. Of the
autopsy-proven cases of aspergillosis in the liver, spleen, and
kidney, CT imaging showed evidence of abscesses in 25% of
patients with hepatic and splenic disease and in none of the
patients with renal involvement. Our patient (patient 4) had
no evidence of abdominal involvement despite proven IFI
with lung nodules on chest CT.
Inpatientswith prior history of IFI,with unexplained fever
and neutropenia, a chest CT may be useful. Other indications
for obtaining a chest CT may include increased respiratory
rate or hypoxia and serially increasing galactomannan.
Empiric chest CT imaging for unexplained fever and neu-
tropenia did not result in alteration of antifungal therapy and
may not be indicated in the absence of localizing signs or
symptoms. In a retrospective study of 52 children with
Pre- allo HSCT patients with CAF evaluation
66
History proven IFI
Respiratory
5
Fungemia
1
Other
1
Abdominal
0
Abnormal Chest CT
9 (3 with history IFI)
Abnormal Abdomen CT
0
Post- allo HSCT patients with initial CAF evaluation
37
Chest CT
37
 Abdomen CT
14
Patients with symptoms
Respiratory
8
Fever
19
Others
10
Abdominal
0
Abnormal Chest CT
3
Abnormal Abdomen CT
0
Change AFT
3
Change AFT
0
Post- allo HSCT patients with F/U CAF evaluation
Chest CT
15 (28 scans)
 Abdomen CT
12 (19 scans)
Patients with symptoms
Respiratory
3
Fever
4
Others
6
Abdominal
2
Abnormal Chest CT
1 (with change AFT)
Abnormal Abdomen CT
0 (no change AFT)
Abbreviations: CAF, computed tomography of the chest and 
abdomen for fungus; HSCT, hematopoietic stem cell transplantation; 
IFI, invasive fungal infection; AFT, anti-fungal therapy.
Figure 1. Patients who had chest and abdominal CT for evaluation of fungus
pretransplant and subsequently post-transplant based on symptomatology.
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malignancies excluding HSCT patients, with 68 unique epi-
sodes of fever and neutropenia who underwent routine CAF
after 4 days of unexplained fever, positive ﬁndings in chest CT
seen in 25 episodes (37%) were not clinically signiﬁcant and
did not lead to changes in antifungal therapy [15]. No patients
showed occult evidence of IFI on abdominal CT [15].
The presence of circulating galactomannanwas predictive
of invasive aspergillosis with a sensitivity of 66% at our
institution [16]. None of our patients had a positive test
for galactomannan pretransplant. Galactomannan and chest
CT-based preemptive antifungal therapy have reduced
antifungal drug use in patients at high risk for IFI [17]. A
meta-analysis that included more than 1770 patients with
hematologic malignancies showed the performance of 2
consecutive b-glucan tests had an excellent speciﬁcity
(98.9%) but a low sensitivity (49.6%) for the diagnosis of IFI
[18]. The use of PCR and other molecular approaches, such as
matrix-assisted laser desorption ionization and ﬂuorescence
in situ hybridization, have proved promising in clinical trials
but still need to undergo standardization before their clinical
use can become widespread [19].
Children and adolescents are at higher risk from exposure
to ionizing radiation from CT for all types of cancer [20,21]. In
keeping with “as low as reasonably achievable radiation”
principles, we recommend reconsideration of routine CAF of
HSCT patients by omitting CT imaging of the abdomen pre-
transplant and replacing it with ultrasound or limited mag-
netic resonance imaging post-transplant when clinically
indicated. Future studies may evaluate the utility of CT im-
aging of the sinuses both pretransplant, and in the setting of
unexplained fever and neutropenia, post-transplant.
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Figure 2. Axial CT images through the lung bases (A) and abdomen (B). (A) Chest image is displayed at a lung window/level, demonstrating multiple, bilateral,
noncalciﬁed pulmonary nodules of various sizes (arrows). (B) A representative image through the upper abdomen shows uniform solid organs and absence of lesions
in the liver, spleen, and kidneys.
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